blu-945
blueprint medicines
['sclc', 'symphony', 'lung', 'nsclc', 'blu-945 ']
#cedarssinaicancer at #asco22. dr. karen reckamp is co-author on the poster a phase 1/2 study of blu-945 in patients with common activating egfr-mutant non small cell lung cancer: symphony trial in progress. #nsclc 
Cedars-Sinai Cancer, ranked #9 in the nation in 2021 by U.S. News & World Report.